Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
Eli Lilly and Company
Thomas Blevins; Dominik Dahl; Federico C Pérez Manghi; Sreenivasa Murthy; Ramon Ortiz Carrasquillo; Xiaoqi Li; Annette M Chang; Molly C Carr; Michelle Katz